Alternate splicing converts human CD137 from costimulatory to immunosuppressive function

IF 6.8 1区 医学 Q1 IMMUNOLOGY
Journal of autoimmunity Pub Date : 2025-12-01 Epub Date: 2025-11-07 DOI:10.1016/j.jaut.2025.103498
Manuel Rojas , Luke S. Heuer , Weici Zhang , Nicolle Sweeney , Carolina Ramírez-Santana , Patrick S.C. Leung , Alvin Lam , Shraddha Kamat , Andrew R. Mendelsohn , Manley Huang , Bo Yu , Paulina Ackerman , Qisheng Wei , James W. Larrick , Yi-Guang Chen , William M. Ridgway
{"title":"Alternate splicing converts human CD137 from costimulatory to immunosuppressive function","authors":"Manuel Rojas ,&nbsp;Luke S. Heuer ,&nbsp;Weici Zhang ,&nbsp;Nicolle Sweeney ,&nbsp;Carolina Ramírez-Santana ,&nbsp;Patrick S.C. Leung ,&nbsp;Alvin Lam ,&nbsp;Shraddha Kamat ,&nbsp;Andrew R. Mendelsohn ,&nbsp;Manley Huang ,&nbsp;Bo Yu ,&nbsp;Paulina Ackerman ,&nbsp;Qisheng Wei ,&nbsp;James W. Larrick ,&nbsp;Yi-Guang Chen ,&nbsp;William M. Ridgway","doi":"10.1016/j.jaut.2025.103498","DOIUrl":null,"url":null,"abstract":"<div><div>Human membrane-bound CD137 (mCD137) is a well-known costimulatory molecule; however, it is alternatively spliced into two transcripts (sCD137-1, 2) whose function is not yet known. Here, we show that sCD137 isoforms lack the CRD4 region and form unique structures compared to mCD137. Human activated Tregs produce both <em>CD137</em> splice isoforms, which are rapidly upregulated after cell activation, and identify an activated Treg phenotype along with <em>FOXP3</em>, <em>CTLA4</em>, and <em>sCTLA4</em>. We engineered recombinant Fc-Hu-sCD137 variants, which are immunosuppressive, inhibiting IFN-γ secretion and proliferation in purified CD4<sup>+</sup> and CD8<sup>+</sup> T cells in an APC-independent manner. These effects are mediated by the downregulation of S6 and 4EBP1 of the mTOR complex 1 pathway. Human sCD137 variants, in contrast to the membrane-bound form, are immunosuppressive and may be a novel treatment for inflammation and autoimmunity.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"157 ","pages":"Article 103498"},"PeriodicalIF":6.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of autoimmunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S089684112500143X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Human membrane-bound CD137 (mCD137) is a well-known costimulatory molecule; however, it is alternatively spliced into two transcripts (sCD137-1, 2) whose function is not yet known. Here, we show that sCD137 isoforms lack the CRD4 region and form unique structures compared to mCD137. Human activated Tregs produce both CD137 splice isoforms, which are rapidly upregulated after cell activation, and identify an activated Treg phenotype along with FOXP3, CTLA4, and sCTLA4. We engineered recombinant Fc-Hu-sCD137 variants, which are immunosuppressive, inhibiting IFN-γ secretion and proliferation in purified CD4+ and CD8+ T cells in an APC-independent manner. These effects are mediated by the downregulation of S6 and 4EBP1 of the mTOR complex 1 pathway. Human sCD137 variants, in contrast to the membrane-bound form, are immunosuppressive and may be a novel treatment for inflammation and autoimmunity.
交替剪接将人CD137从共刺激功能转化为免疫抑制功能
人膜结合CD137 (mCD137)是一种众所周知的共刺激分子;然而,它被选择性地拼接成两个功能尚不清楚的转录本(scd137 - 1,2)。在这里,我们发现sCD137异构体缺乏CRD4区域,与mCD137相比形成独特的结构。人类活化的Treg产生CD137剪接异构体,在细胞活化后迅速上调,并与FOXP3, CTLA4和sCTLA4一起鉴定出活化的Treg表型。我们设计了重组Fc-Hu-sCD137变体,该变体具有免疫抑制作用,以不依赖apc的方式抑制纯化CD4+和CD8+ T细胞中IFN-γ的分泌和增殖。这些作用是通过mTOR复合物1通路中S6和4EBP1的下调介导的。与膜结合形式相反,人类sCD137变体具有免疫抑制作用,可能是治疗炎症和自身免疫的一种新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of autoimmunity
Journal of autoimmunity 医学-免疫学
CiteScore
27.90
自引率
1.60%
发文量
117
审稿时长
17 days
期刊介绍: The Journal of Autoimmunity serves as the primary publication for research on various facets of autoimmunity. These include topics such as the mechanism of self-recognition, regulation of autoimmune responses, experimental autoimmune diseases, diagnostic tests for autoantibodies, as well as the epidemiology, pathophysiology, and treatment of autoimmune diseases. While the journal covers a wide range of subjects, it emphasizes papers exploring the genetic, molecular biology, and cellular aspects of the field. The Journal of Translational Autoimmunity, on the other hand, is a subsidiary journal of the Journal of Autoimmunity. It focuses specifically on translating scientific discoveries in autoimmunity into clinical applications and practical solutions. By highlighting research that bridges the gap between basic science and clinical practice, the Journal of Translational Autoimmunity aims to advance the understanding and treatment of autoimmune diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书